ACT 178882
Modify Date: 2024-02-26 19:53:25
ACT 178882 structure
|
Common Name | ACT 178882 | ||
|---|---|---|---|---|
| CAS Number | 1007392-69-9 | Molecular Weight | 647.031 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 764.3±60.0 °C at 760 mmHg | |
| Molecular Formula | C33H38Cl3N3O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 416.0±32.9 °C | |
Use of ACT 178882ACT 178882 is a new Renin inhibitor with an IC50 of 1.4 nM. |
| Name | ACT 178882 |
|---|---|
| Synonym | More Synonyms |
| Description | ACT 178882 is a new Renin inhibitor with an IC50 of 1.4 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.4 nM (Renin)[1] |
| In Vitro | The median time to Cmax (tmax) for ACT 178882 is prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t½) is unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively. Using treatment A as reference, the geometric mean ratio (90% CI) is 1.62 (1.36 to 1.94) for Cmax and 2.02 (1.75 to 2.34) for AUC∞, indicating a significant interaction between ACT 178882 and diltiazem[2]. |
| Cell Assay | Venous blood samples for the determination of ACT 178882 are drawn at the following time points: pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96 and 120 h after dosing with ACT 178882 in treatment A and pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216 and 240 h after dosing with ACT178882 in treatment B. For diltiazem as soon as possible after collection, and for ACT-178882 within maximally 30 minutes after collection, the tubes are centrifuged and the plasma separated. All samples are stored in an upright position at -20 °C (ACT 178882) or -80 °C (diltiazem) or below pending analysis[2]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 764.3±60.0 °C at 760 mmHg |
| Molecular Formula | C33H38Cl3N3O4 |
| Molecular Weight | 647.031 |
| Flash Point | 416.0±32.9 °C |
| Exact Mass | 645.192810 |
| LogP | 6.12 |
| Vapour Pressure | 0.0±2.6 mmHg at 25°C |
| Index of Refraction | 1.623 |
| (3R,4S)-N-[2-Chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-4-{6-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]-3-pyridinyl}-3-piperidinecarboxamide |
| 3-Piperidinecarboxamide, N-[[2-chloro-5-(2-methoxyethyl)phenyl]methyl]-N-cyclopropyl-4-[6-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]-3-pyridinyl]-, (3R,4S)- |